glp 1 based therapy Expanding applications of therapies on GLP1 Insights into incretin-based therapies for
Description
doi:10.1186/ar2965 70

Safety profile The safety assessment of GLP-1 receptor agonists indicates a mostly gastrointestinal side effect profile, characterised by dose-dependent symptoms that are often treatable by meticulous titration (Madsbad 2016)

Bando, H

Genetically predicted lower HbA1c showed limited association with mental health outcomes, except for MDD

Conditions like gastroparesis , a disorder that affects stomach muscle function and delays stomach emptying, may worsen with GLP-1 use

No, there is no direct conversion chart from Mounajro to Ozempic
